Plus   Neg

Patterson Boosts FY20 Adj. EPS Outlook - Quick Facts

While reporting financial results for the second quarter on Thursday, Patterson Companies Inc. (PDCO) raised its adjusted earnings guidance for the full-year 2020.

"As a result of the progress we have made against our strategic priorities during the first two quarters of fiscal 2020, we are raising our adjusted earnings guidance for the year," said Mark Walchirk, President and CEO of Patterson Companies.

For fiscal 2020, the company now projects earnings in a range of $0.42 to $0.52 per share and adjusted earnings in a range of $1.36 to $1.46 per share.

The company had previously projected earnings in the range of $1.13 to $1.23 per share and adjusted earnings in the range of $1.33 to $1.43 per share.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $1.37 per share for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT